This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents. How will payers pay for these new gene therapies? Did Novartis set the price reference for Juno’s and Gilead/Kite’s CAR-T entrants?

Click here to see full size image